Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Spectrum Pharmaceuticals ( SPPI - Snapshot Report ) is a step closer to acquiring Allos Therapeutics ( ) with the companies announcing the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
The US Federal Trade Commission (FTC) cleared the acquisition of Allos by Spectrum Pharma which is expected to close on September 4, 2012. Spectrum Pharma stated that it will accept for payment shares of Allos validly tendered prior to the expiration of the buyout offer on September 4 (5pm ET).
Spectrum Pharma had announced its intention to acquire biopharmaceutical company, Allos in April 2012. Per the terms of the deal, Spectrum Pharma will acquire Allos for $1.82 per share in cash along with one contingent value right (CVR).
The CVR, which will not be traded in the public domain, makes each Allos shareholder eligible to receive a further $0.11 per share in cash depending on the conditional European approval and achievement of certain milestones of Allos’ sole marketed drug, Folotyn.
We remind investors that Folotyn is available in the US for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Currently, Spectrum Pharma’s product portfolio comprises two marketed products -Fusilev used for treating advanced metastatic colorectal cancer and for rescue in osteosarcoma (a form of bone cancer) patients following treatment with a high-dose of chemotherapy drug, methotrexate and Zevalin for treating patients suffering from non-Hodgkin’s lymphoma.
The addition of Folotyn will further strengthen the oncology portfolio of Spectrum Pharma. At the time of announcing the deal, management at Spectrum Pharma had stated that both Zevalin and Folotyn will target the same set of doctors for treating different cancer forms. This makes the deal all the more sound strategically.
Our Recommendation
Currently, we have a Neutral recommendation on Allos in the long run. The stock carries a Zacks #3 Rank (Hold rating) in the short run. However, we have an Underperform recommendation on Spectrum Pharma. The company carries a Zacks #5 Rank (Strong Sell) in the short run.
Read the full Snapshot Report on SPPI